Clinical Trial Update: Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CAR-T cells targeting CLL-1 (CLEC12A) for acute myeloid leukemia; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CLL-1 targeted CAR-T therapy (CAR-T cell therapy targeting CLEC12A (CLL-1))

Snippet

Sponsor: Baylor College of Medicine | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING